Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 21:12:291.
doi: 10.1186/s12967-014-0291-1.

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

Paolo A Ascierto  1 , Raffaele Addeo  2 , Giacomo Cartenì  3 , Bruno Daniele  4 , Michele De Laurentis  5 , Giovanni Pietro Ianniello  6 , Alessandro Morabito  7 , Giovannella Palmieri  8 , Stefano Pepe  9 , Francesco Perrone  10 , Sandro Pignata  11 , Vincenzo Montesarchio  12
Affiliations
Review

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

Paolo A Ascierto et al. J Transl Med. .

Abstract

The therapeutic approach to advanced or metastatic solid tumors, either with chemotherapy or targeted therapies, is mainly palliative. Resistance to chemotherapy occurs very frequently and is one of the most important reasons for disease progression. Immunotherapy has the potential to mount an ongoing, dynamic immune response that can kill tumor cells for an extended time after the conventional therapy has been administered. Such a long-lasting response is potentially able to completely eradicate tumor cells, rather than producing only a temporary killing of cells. The most promising immune-based treatments are monoclonal antibodies that act as checkpoint inhibitors (e.g. ipilimumab and nivolumab), adoptive cell therapy (e.g. T-cells expressing chimeric antigen receptors) and vaccines (e.g. sipuleucel-T). Ipilimumab is currently approved for the treatment of metastatic melanoma and sipuleucel-T is approved for advanced prostate cancer. There is great interest in immunotherapy in other solid tumors, potentially used alone or in a multimodal fashion with chemotherapy and/or biological drugs. In this paper, we review recent advances in immuno-oncology in solid malignancies (except melanoma) as were discussed at the inaugural meeting of the Campania Society of Oncology Immunotherapy (SCITO).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ipilimumab clinical activity (OS) irrespective of BRAF mutational status: the Italian EAP in melanoma by Ascierto et al. J Trans Med 2014; 12: 116–122 [ 26 ].
Figure 2
Figure 2
Ipilimumab clinical activity (OS) irrespective of NRAS mutational status: the Italian EAP in melanoma by Ascierto et al. J Trans Med 2014; 12: 116–122 [ 26 ].
Figure 3
Figure 3
OS improvement in the treatment of advanced mHNC adding anti-EGFR MoAbs to chemotherapy [ 74 , 76 ].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Burnet FM. Cancer a biological approach. Br Med J. 1957;1:841–847. doi: 10.1136/bmj.1.5023.841. - DOI - PMC - PubMed
    1. Vesely MD, Kershaw MH, Schreiber RD. Natural innate and adaptive immunity to cancer. Ann Rev Immunol. 2011;29:235–271. doi: 10.1146/annurev-immunol-031210-101324. - DOI - PubMed
    1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–213. doi: 10.1056/NEJMoa020177. - DOI - PubMed
    1. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275–280. doi: 10.1038/sj.bjc.6602934. - DOI - PMC - PubMed
    1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi: 10.1126/science.1129139. - DOI - PubMed

Publication types

-